The Disease Burden and Molecular Case for New Therapies

Sickle cell disease (SCD) is a monogenic hemoglobinopathy caused by a single-nucleotide HBB Glu6Val substitution that drives hemoglobin S (HbS) polymerization under deoxygenated conditions, resulting in erythrocyte sickling, vaso-occlusive crises, and multi-organ damage — with life expectancy reduced to just 42–48 years. HbS/S homozygosity accounts for 60–70% of SCD cases in the United States, according to multiple Beam Therapeutics patent filings, with compound genotypes including HbS-beta zero thalassemia and HbSC disease representing additional clinically significant populations.

The approval of Casgevy — the first CRISPR-based gene editing therapy for SCD — established a transformative precedent, but its procedural complexity and cost have focused the field’s attention on the next challenge: developing therapies that are more accessible, combinable with existing agents, and applicable to the full spectrum of SCD genotypes. According to WHO, SCD affects millions of people globally, with the highest burden in sub-Saharan Africa — a population largely unreachable by current ex vivo cell therapy paradigms.

The molecular architecture of SCD creates multiple druggable entry points. Direct correction of the causal HBB SNP, reactivation of fetal hemoglobin (HbF) to compete with HbS, metabolic reprogramming of red blood cells to reduce HbS polymerization, and inhibition of vascular adhesion pathways are all independently viable therapeutic strategies — and the patent landscape now reflects serious commercial investment in each of them.

ABE8 Base Editing and Prime Editing: Correcting the Root Cause

Adenosine base editing using the ABE8 class of modified deaminase enzymes is the most densely patented therapeutic modality in the SCD pipeline, with Beam Therapeutics holding more than 20 distinct filings across US, CA, WO, AU, SG, IN, JP, and CN jurisdictions — all directed at executing an A•T → G•C conversion at the HBB sickle SNP with editing efficiencies exceeding 60–70% in CD34+ hematopoietic stem cells (HSCs). This directly reverses the Glu6Val pathogenic substitution, restoring functional HbA rather than relying on HbF competition.

Beam’s portfolio also covers dual-editing strategies that simultaneously target the HBB SNP and the HBG1/2 promoter BCL11A binding sites (positions −114, −117, −175, and −198), potentially enabling both direct HBB correction and HbF-mediated protection in the same edited cell population. Engraftment patents specify endpoints including sustained HbF expression for at least 8 weeks and at least 16 weeks post-administration — language consistent with IND-enabling or early clinical protocol design.

The Broad Institute’s 2024 WO patent on prime editing for SCD represents a mechanistically distinct approach: prime editing corrects the HBB sickle SNP using epegRNAs without introducing double-strand DNA breaks, reducing the risk of large deletions or chromosomal rearrangements associated with nuclease-based editing. Red blood cells derived from prime-edited SCD HSPCs showed up to 42% increase in normal adult hemoglobin (HbA) and resistance to hypoxia-induced sickling. An analysis of over 100 candidate off-target sites nominated by genome-wide approaches detected minimal off-target editing — a dataset consistent with IND-enabling preclinical safety characterization.

“Red blood cells derived from prime-edited SCD HSPCs showed up to 42% increase in normal adult hemoglobin and resistance to hypoxia-induced sickling, with minimal off-target editing across more than 100 candidate sites.”

INSERM’s 2023 WO filing on base editing of the BCL11A +55-kb enhancer adds an important academic counterpoint: the disclosure reports an absence of indels in base-edited samples (measured by TIDE analysis) while achieving BCL11A downregulation, HbF reactivation, and sickling phenotype rescue in SCD HSPCs — demonstrating that base editing at regulatory rather than coding loci can achieve therapeutic HbF levels without introducing insertions or deletions.

Fetal Hemoglobin Induction: The BCL11A Axis and Beyond

The BCL11A/HbF axis is the most heavily contested therapeutic target in the SCD pipeline, with at least six distinct organisations — Beam Therapeutics, Editas Medicine, Children’s Medical Center Corporation, INSERM, Dana-Farber Cancer Institute, and CRISPR Therapeutics — independently claiming BCL11A disruption strategies in this dataset. BCL11A functions as the principal transcriptional repressor of gamma-globin genes HBG1 and HBG2; disrupting its erythroid-specific enhancer or its binding sites in the HBG1/2 promoter region reactivates fetal hemoglobin expression, which competes with HbS in red blood cells to reduce polymerization and sickling.

Editas Medicine’s CRISPR-Cpf1 (Cas12a) and Cas9-mediated editing of HBG1 and HBG2 promoter loci in CD34+ HSPCs achieves ≥60–95% deletions of ≥4 bp at target sites, with significantly decreased sickling and improved elongation indices reported in patent filings. Dana-Farber Cancer Institute’s 2025 patent on tandem shmiR constructs targeting both BCL11A and Zfp410 simultaneously demonstrates superior gamma-globin reactivation and SCD phenotype rescue — including reduced spleen mass in a mouse model — compared to single-target knockdown, suggesting that combination transcription factor silencing is a more potent HbF induction strategy.

Beyond gene editing, RNA interference approaches are also represented. The U.S. Department of Health and Human Services holds patents claiming ribonucleotide agents — including antisense oligonucleotides, shRNA, siRNA, aiRNA, microRNA, and ribozymes — that decrease expression of RIOK3, a kinase whose knockdown is claimed to treat SCD. A Chinese national-phase filing describes co-knockdown of BCL11A alongside RIOK3 as a dual-target strategy, suggesting that RIOK3 and BCL11A may act through complementary mechanisms in erythroid cells. Boston Children’s Hospital (Children’s Medical Center Corporation) filings describe synthetic BCL11A-targeting microRNAs expressed from RNA Pol II vectors for HbF induction in hematopoietic and progenitor cells.

Novartis has identified WIZ (Widely Interspaced Zinc Finger Motifs) as a novel HbF repressor target, distinct from BCL11A. A 2023 Novartis patent filing describes pyrazolopyridine derivatives that reduce WIZ expression and induce HbF for treatment of beta-hemoglobinopathies — representing a small molecule path to HbF induction that operates through a different transcriptional mechanism than BCL11A-targeting approaches, according to EBI gene function databases.

Small Molecule Strategies: Epigenetic, Metabolic, and Anti-Sickling Approaches

Small molecule approaches to SCD span three mechanistically distinct categories: epigenetic de-repression of gamma-globin to induce HbF, metabolic reprogramming of red blood cells to reduce HbS polymerization, and direct anti-sickling via modification of the HbS N-terminus. Each offers potential oral bioavailability and combination utility with approved agents — properties that gene editing therapies cannot currently match for the majority of the global SCD patient population.

Epigenetic HbF Induction

Three epigenetic targets are represented in this dataset. Epizyme (now Syndax Pharmaceuticals) filed a PCT application covering EHMT2 (G9a histone H3K9 methyltransferase) inhibitors to treat blood disorders via epigenetic de-repression of gamma-globin. Oric Pharmaceuticals’ 2025 WO application claims PRC2 (Polycomb Repressive Complex 2) inhibitors for SCD treatment, explicitly positioning them for patients previously treated with hydroxyurea, voxelotor, crizanlizumab, or L-glutamine — signalling intent for a combination trial design as an add-on to existing standard-of-care agents. Novartis’ WIZ-targeting pyrazolopyridines (2023) provide a third epigenetic mechanism. The convergence of three separate companies on epigenetic HbF induction via distinct mechanisms suggests that the field views epigenetic de-repression of gamma-globin as a validated, commercially viable strategy, consistent with guidance from NIH on hemoglobin switching mechanisms.

Metabolic Reprogramming: PKR Activation

Forma Therapeutics holds patents on pyrrolopyrrole compounds as pyruvate kinase R (PKR) activators for SCD treatment. The mechanism involves restoration of ATP levels in red blood cells, reduction of 2,3-DPG, and consequent decrease in HbS deoxygenation-driven polymerization. Agios Pharmaceuticals’ mitapivat analogs (represented in Chinese-language filings) signal convergent commercial interest in PKR activation as a non-HbF, non-gene-editing approach to reducing HbS polymerization — a mechanistically differentiated path that may be particularly relevant for patients with compound SCD genotypes.

MetAP2 Inhibition: A Novel Anti-Polymerization Mechanism

University of Minnesota researchers published evidence that MetAP2 (methionine aminopeptidase 2) inhibition blocks cleavage of the initiator methionine from beta-S-globin N-termini, leading to stable acetyl-iMet retention and resistance to HbS polymerization. Beta-S-globin peptide was found to be a 5-fold better MetAP2 substrate than alpha-globin in kinetic studies — a selectivity ratio that could support a therapeutic window for anti-sickling intervention. This mechanism is entirely distinct from HbF induction or direct HBB correction, and represents an academic-originated target with no commercial patent activity yet recorded in this dataset.

Combination Strategies and Emerging Delivery Modalities

The most strategically significant signals in this dataset are not individual targets but combinations and delivery innovations that address the two principal bottlenecks in SCD gene therapy: procedural toxicity from myeloablative conditioning, and geographic inaccessibility of ex vivo cell therapy infrastructure. Multiple retrieved results converge on both problems simultaneously.

Beam Therapeutics’ 2025 patent filings describe non-genotoxic conditioning via multiplexed base editing of the CD117 (c-KIT) antigen in HSCs alongside the therapeutic SCD edit. The approach renders edited cells resistant to anti-CD117 antibody depletion while enabling selective elimination of unedited cells — allowing antibody-based conditioning to replace genotoxic chemotherapy without sacrificing engraftment selectivity. This represents a meaningful reduction in transplant-associated toxicity for patients who currently require myeloablative regimens.

University of British Columbia filings describe lipid-based transfection-competent vesicles (TCVs) for in vivo delivery of gene editing components directly to bone marrow cells, potentially bypassing the ex vivo HSC harvest and re-infusion cycle entirely. If demonstrated in human studies, in vivo delivery would represent a paradigm shift in accessibility — transforming gene editing from a procedure requiring specialized transplant infrastructure into one potentially administrable in outpatient settings. According to WIPO‘s global IP data, in vivo delivery platforms currently represent a less crowded IP space than ex vivo base editing, suggesting greater freedom-to-operate for new entrants.

Complement inhibition represents a further mechanistically distinct direction: an Alexion Pharmaceuticals (now AstraZeneca) Chinese patent application describes anti-C5 antibodies and complement alternative pathway inhibitors for SCD vaso-occlusion, based on data showing C5b-9 and C3 deposition on SCD red blood cells under hypoxia. Pfizer holds multiple filings on anti-E-selectin antibodies for SCD vaso-occlusion, including combination use with hydroxyurea, L-glutamine, voxelotor, and crizanlizumab — extending the vascular biology approach to include both complement and adhesion pathways. The clinical signal from L-glutamine is the strongest explicit efficacy datapoint in this dataset: pharmaceutical-grade L-glutamine reduced vaso-occlusive crises by 45% in SCD patients in a re-analysis of Phase 3 trial data reported by the Centre de Référence de la Drépanocytose, Martinique.

IP Landscape and Strategic Implications for the SCD Pipeline

Beam Therapeutics holds the deepest patent position in base editing for SCD in this dataset, with filings spanning multiple jurisdictions and covering both direct HBB correction and HbF induction strategies. Any developer or IP strategist entering the base editing space will need to design around or license from Beam’s ABE8 portfolio. The Broad Institute’s 2024 prime editing WO patent and the University of British Columbia’s in vivo delivery filings represent potentially disruptive next-generation modalities with IP positions currently less crowded than ex vivo base editing — areas where early-stage investors and academic collaborators may find greater freedom-to-operate.

The convergence of at least six distinct organisations on the BCL11A/HbF axis indicates high commercial interest but also potential freedom-to-operate complexity for new entrants. The diversity of mechanisms — ABE8 base editing, CRISPR-Cpf1 nuclease, shmiR dual knockdown, BCL11A-targeting microRNA, and pyrazolopyridine small molecules — means that IP positions are differentiated by mechanism even when the ultimate therapeutic target is shared. Developers should map their specific approach against the full claims landscape, not just the target, before committing to a development programme. According to EPO patent data, the SCD gene editing filing rate has accelerated substantially since 2019, consistent with the post-CRISPR therapeutic wave.

“Non-genotoxic conditioning strategies and in vivo delivery vectors are both emerging in this dataset, signalling that field maturation is shifting attention from editing efficiency toward reducing the procedural burden of ex vivo cell therapy — a critical consideration for global SCD patient populations where infrastructure for bone marrow transplant is limited.”

Small molecule HbF inducers targeting epigenetic machinery (PRC2, EHMT2, WIZ) represent a non-gene-editing path to HbF induction with oral bioavailability potential. Oric, Epizyme, and Novartis each hold distinct IP positions on different epigenetic mechanisms, suggesting continued commercial interest in this approach — particularly as combination partners with existing approved therapies or as alternatives for patients ineligible for gene editing. Flagship Pioneering Innovations VI holds WO and US patents on perturbagen-based HbF induction methods, positioning a further distinct approach to erythroid cell state reprogramming. The PatSnap Life Sciences intelligence platform and PatSnap BioPharma analytics tools enable systematic monitoring of these rapidly evolving IP positions across all jurisdictions.